WINT news & sentiment — WINDTREE THERAPEUTICS INC /DE/

MAR 12·MarketBeatMed

WINTON GROUP Ltd Has $1.22 Million Stake in NetApp, Inc. $NTAP

WINTON GROUP Ltd significantly reduced its stake in NetApp, Inc. by 81.9% in the 3rd quarter, now holding 10,262 shares valued at $1.22 million. Despite this, other institutional investors increased their positions, and NetApp recently reported strong quarterly earnings, beating analyst estimates, and declared a quarterly dividend. Analysts maintain a "Moderate Buy" rating with an average target price of $122.42 for the data storage provider.

DEC 12·MarketBeat

WINTON GROUP Ltd Invests $710,000 in Regeneron Pharmaceuticals, Inc. $REGN

WINTON GROUP Ltd has acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 1,353 shares valued at approximately $710,000. Other institutional investors have also adjusted their holdings in REGN, with a consensus "Moderate Buy" rating and a target price of $779.41 from analysts. The article also details recent insider transactions and the company's financial performance.

NOV 14·Benzinga

Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate - Windtree Therapeutics ( OTC:WINT )

Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute heart failure in Canada and Mexico The pure SERCA2a activators patent for acute heart failure was ...

$WINT

WINTON GROUP Ltd Has $1.22 Million Stake in NetApp, Inc. $NTAP

WINTON GROUP Ltd Invests $710,000 in Regeneron Pharmaceuticals, Inc. $REGN

Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate - Windtree Therapeutics ( OTC:WINT )

News on $WINT